Codexis (CDXS) Gains from Equity Investments (2014)
Codexis' (CDXS) quarterly Gains from Equity Investments came in at $131000.0 in Q3 2014.
Codexis (CDXS) Gains from Equity Investments (2014) Analysis & Trends
Codexis' Gains from Equity Investments history runs 1 years deep, the most recent figure standing at $131000.0 for Q3 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn |
| 10 | Codexis | 140.24 Mn | 75.10 Mn | 13.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 131,000.00 |
| Sep 30, 2014 | 131,000.00 |